Today, the Biomedical Advanced Research and Development Authority (BARDA) announced the launch of the Patch Forward Prize, a $50 million Project NextGen competition to advance microneedle patch-based RNA vaccines. BARDA calls on vaccine developers and patch makers to partner and accelerate new vaccine technologies.
The Patch Forward Prize is a unique funding mechanism to foster industry collaboration and support the advancement of patch-based vaccine candidates toward the completion of Phase I clinical trials. By demonstrating the safety and immunogenicity of patch-based RNA vaccines in humans, the prize will accelerate breakthroughs in vaccine technology.
Initiate partnerships and start development plans
The initial stage of the prize invites eligible entrants — namely RNA vaccine developers and patch makers engaging in strategic partnerships — to submit concept papers detailing their respective technologies, proposed product, plans for development, and functional testing.
The concept papers are expected to address key considerations for product development and formulation, regulatory review and approval, preclinical and clinical evaluation, and manufacturing processes to advance a safe, tolerable, and immunogenic patch-based RNA vaccine. The vaccine product must include at least one of the following indications: COVID-19, trivalent or quadrivalent seasonal influenza, and/or pandemic influenza A/H5N1. Prospective entrants can preview the submission form, multistage timeline, award details, and evaluation criteria.
Connect with potential prize partners at the World Vaccine Congress
The Patch Forward Prize team is attending the World Vaccine Congress in Washington, D.C. from April 1 to April 3. To support partnership and teaming for the prize, we have reserved meeting spaces near the conference to help facilitate private conversations and connections. Reach out to hello@patchforwardprize.com to inquire about booking space for meetings with potential partners.
Attend the virtual information session on April 18
Register for the April 18 virtual information session to learn more and hear from Dr. Robert Johnson, Director of BARDA’s Medical Countermeasures Program. The Patch Forward Prize team will discuss the three stages of the prize, exploring submission expectations, eligibility requirements, and other key considerations. The session will conclude with a live Q&A.
Browse entrant resources
Access curated resources related to vaccine patch technology, product development, and regulatory navigation.